{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Jim+Shannon&answer.groupedQuestionUIN=99838&min-answer.questionFirstAnswered.=2019-05-15T12%3A38%3A15.39Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Jim+Shannon&answer.groupedQuestionUIN=99838&min-answer.questionFirstAnswered.=2019-05-15T12%3A38%3A15.39Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Jim+Shannon&answer.groupedQuestionUIN=99838&min-answer.questionFirstAnswered.=2019-05-15T12%3A38%3A15.39Z&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Jim+Shannon&_page=0&answer.groupedQuestionUIN=99838&min-answer.questionFirstAnswered.=2019-05-15T12%3A38%3A15.39Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Jim+Shannon&answer.groupedQuestionUIN=99838&min-answer.questionFirstAnswered.=2019-05-15T12%3A38%3A15.39Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Jim+Shannon&answer.groupedQuestionUIN=99838&min-answer.questionFirstAnswered.=2019-05-15T12%3A38%3A15.39Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1546762", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1546762/answer", "answerText" : {"_value" : "<p>As part of the consultation process undertaken in 2020 and 2022, we updated the Branded medicines: statutory scheme. Impact assessments were conducted to understand the drivers of changes to measured sales in the voluntary scheme for branded medicines pricing and access (VPAS).<\/p><p> <\/p><p>The 2020 and 2022 assessments are available at the following links:<\/p><p> <\/p><p><a href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/871361/final-impact-assessment-statutory-scheme-2020.pdf\" target=\"_blank\">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/871361/final-impact-assessment-statutory-scheme-2020.pdf<\/a><\/p><p> <\/p><p><a href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1079733/Statutory_Scheme_impact_assessment_medicine_pricing_v3.0_FINALdated_May_2022.pdf\" target=\"_blank\">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1079733/Statutory_Scheme_impact_assessment_medicine_pricing_v3.0_FINALdated_May_2022.pdf<\/a><\/p><p> <\/p><p>Under the rules of VPAS, there is no requirement for regular assessment of whether scheme members\u2019 profits exceed the margin of tolerance. Under the 2014 Pharmaceutical Price Regulation Scheme where such a requirement was in place, no companies were found to have exceeded the margin of tolerance in 2017 or 2018.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2022-12-08", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "99838"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-12-08T17:20:48.443Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-11-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Voluntary Scheme for Branded Medicines Pricing and Access"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many member companies of the Voluntary Scheme for Branded Medicines Pricing and Access have reported profits in excess of the margin of tolerance in each of the past five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "99839"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}